Determination of fluoxetine enantiomers in human serum and urine by isocratic HPLC and pre-column fluorescence derivatization with (R)-(+)-4-nitro-7-(2-chloroformylpyrrolidin-1-YL)-2,1,3-benzoxadiazole

Journal of Liquid Chromatography and Related Technologies

Volumn 33, Issue 4, 2010, Pages 481-490

  Higashi, Yasuhiko ^a   Gao, Ranzhi ^a   Fujii, Youichi ^a  

^a HOKURIKU UNIVERSITY   (Japan)

Author keywords

(R) (+) 4 nitro 7 (2 chloroformylpyrrolidin 1 yl) 2,1,3 benzoxadiazole; Enantiomer; Fluorescence detection; Fluoxetine; Pre column derivatization

Indexed keywords

BORATE BUFFER; COEFFICIENTS OF VARIATIONS; DERIVATIZATIONS; DETECTION LIMITS; FLUORESCENCE DERIVATIZATION; FLUORESCENCE DETECTION; FLUOXETINE; HPLC METHOD; HUMAN SERUM; HUMAN URINE; INTERNAL STANDARDS; ISOCRATIC; PRECOLUMN DERIVATIZATIONS; REGRESSION EQUATION; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SIMULTANEOUS DETERMINATIONS; THERAPEUTIC DRUG MONITORING;

CHIRALITY; ENANTIOMERS; EXTRACTION; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; PARAFFINS; PATIENT MONITORING; POLYMORPHISM;

BODY FLUIDS;

4 NITRO 7 (2 CHLOROFORMYLPYRROLIDIN 1 YL) 2,1,3 BENZOXADIAZOLE; BORIC ACID; BUFFER; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; MAPROTILINE; NORTRIPTYLINE; OXADIAZOLE DERIVATIVE; PAROXETINE; PENTANE; PROTRIPTYLINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; DRUG URINE LEVEL; ENANTIOMER; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH; STANDARD; TEMPERATURE;

EID: 76749156313     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070903574428     Document Type: Article

References (18)

1. Schmidt, M.J.; Fuller, R.W.; Wong, D.T. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br. J. Psychiatry Suppl. 1988, 3, 40-46.
2. Lemberger, L.; Rowe, H.; Carmichael, R.; Crabtree, R.; Horng, J.S.; Bymaster, F.; Wong, D. Fluoxetine, a selective serotonin uptake inhibitor. Clin. Pharmacol. Ther. 1978, 23, 421-429.
3. Wong, D.T.; Fuller, R.W.; Robertson, D.W. Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm. Nord. 1990, 2, 171-180.
4. Robertson, D.W.; Krushinski, J.H.; Fuller, R.W.; Leander, J.D. Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor. J. Med. Chem. 1988, 31, 1412-1417.
5. Guo, X.; Fukushima, T.; Li, F.; Imai, K. Determination of fluoxetine enantiomers in rat plasma by pre-column fluorescence derivatization and column-switching high-performance liquid chromatography. Analyst 2002, 127, 480-484.
6. Gatti, G.; Bonomi, I.; Marchiselli, R.; Fattore, C.; Spina, E.; Scordo, G.; Pacifici, R.; Perucca, E. Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. J. Chromatogr. B 2003, 784, 375-383.
7. Jannuzzi, G.; Gatti, G.; Magni, P.; Spina, E.; Pacifici, R.; Zuccaro, P.; Torta, R.; Guarneri, L.; Perucca, E. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther. Drug Monit. 2002, 24, 616-627.
8. Suckow, R.F.; Zhang, M.F.; Cooper, T.B. Sensitive and selective liquid-chromatographic assay of fluoxetine and norfluoxetine in plasma with fluorescence detection after precolumn derivatization. Clin. Chem. 1992, 38, 1756-1761.
9. Kovacevic, I.; Pokrajac, M.; Miljkovic, B.; Jovanovic, D.; Prostran, M. Comparison of liquid chromatography with fluorescence detection to liquid chromatography-mass spectrometry for the determination of fluoxetine and norfluoxetine in human plasma. J. Chromatogr. B 2006, 830, 372-376.
10. Juan, H.; Zhiling, Z.; Huande, L. Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS=ESI). J. Chromatogr. B 2005, 820, 33-39.
11. Higashi, Y.; Gao, R.; Fujii, Y. Determination of fluoxetine and norfluoxetine in human serum and urine by HPLC using a cholester column with fluorescence detection. J. Liq. Chromatogr. & Rel. Technol. 2009, 32, 1141-1151.
12. Fukushima, T.; Naka-aki, E.; Guo, X.; Li, F.; Vankeirsbilck, T.; Baeyens, W.R.G.; Imai, K.; Toyo'oka, T. Determination of fluoxetine and norfluoxetine in rat brain microdialysis samples following intraperitoneal fluoxetine administration. Anal. Chim. Acta 2004, 522, 99-104.
13. Unceta, N.; Barrondo, S.; de Azúa, I.R.; Gómez-Caballero, A.; Goicolea, M.A.; Sallés, J.; Barrio, R.J. Determination of fluoxetine, norfluoxetine and their enantiomers in rat plasma and brain samples by liquid chromatography with fluorescence detection. J. Chromatogr. B 2007, 852, 519-528.
14. Torok-Both, G.A.; Baker, G.B.; Coutts, R.T.; McKenna, K.F.; Aspeslet, L.J. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J. Chromatogr. 1992, 579, 99-106.
15. Eap, C.B.; Gaillard, N.; Powell, K.; Baumann, P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J. Chromatogr. B 1996, 682, 265-272.
16. Altamura, A.C.; Moro, A.R.; Percudani, M. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 1994, 26, 201-214.
17. Wong, D.T.; Bymaster, F.P.; Reid, L.R.; Mayle, D.A.; Krushinski, J.H.; Robertson, D.W. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 1993, 8, 337-344.
18. Baumann, P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 1996, 31, 444-469